| The cost of pushing pills: a new estimate of pharmaceutical promotion expenditures in the United States MA Gagnon, J Lexchin Plos medicine 5 (1), e1, 2008 | 742 | 2008 |
| Corruption of pharmaceutical markets: addressing the misalignment of financial incentives and public health MA Gagnon Journal of Law, Medicine & Ethics 41 (3), 571-580, 2013 | 114 | 2013 |
| The economic case for universal pharmacare: costs and benefits of publicly funded drug coverage for all Canadians MA Gagnon, G Hébert Canadian Centre for Policy Alternatives= Centre canadien de politiques …, 2010 | 72 | 2010 |
| The future of drug coverage in Canada JR Daw, B Mintzes, SG Morgan, MA Gagnon, D Martin, J Lexchin The Pharmaceutical Policy Research Collaboration, University of British Columbia, 2015 | 64* | 2015 |
| The nature of capital in the knowledge-based economy: The case of the global pharmaceutical industry MA Gagnon York University, 2009 | 60 | 2009 |
| Analyzing the impact of trade and investment agreements on pharmaceutical policy: provisions, pathways and potential impacts D Gleeson, J Lexchin, R Labonté, B Townsend, MA Gagnon, J Kohler, ... Globalization and Health 15, 1-17, 2019 | 57 | 2019 |
| Capital, power and knowledge according to Thorstein Veblen: Reinterpreting the knowledge-based economy MA Gagnon Journal of Economic Issues 41 (2), 593-600, 2007 | 52 | 2007 |
| Merger mania: mergers and acquisitions in the generic drug sector from 1995 to 2016 MA Gagnon, KD Volesky Globalization and health 13, 1-7, 2017 | 50 | 2017 |
| CETA and pharmaceuticals: impact of the trade agreement between Europe and Canada on the costs of prescription drugs J Lexchin, MA Gagnon Globalization and Health 10, 1-6, 2014 | 46 | 2014 |
| A roadmap to a rational pharmacare policy in Canada MA Gagnon Canadian Federation of Nurses Unions, 2014 | 43 | 2014 |
| Mirror, mirror on the wall: Medicare Part D pays needlessly high brand-name drug prices compared with other OECD countries and with US government programs MA Gagnon, S Wolfe Carleton University, 2015 | 32* | 2015 |
| Combating corruption in the pharmaceutical arena J Lexchin, JC Kohler, MA Gagnon, J Crombie, P Thacker, A Shnier Indian Journal of Medical Ethics 3 (3), 234-239, 2018 | 31 | 2018 |
| Whose shoulders is health research standing on? Determining the key actors and contents of the prevailing biomedical research agenda FE Testoni, M García Carrillo, MA Gagnon, C Rikap, M Blaustein PloS one 16 (4), e0249661, 2021 | 30 | 2021 |
| New drug pricing: does it make any sense? MA Gagnon Prescrire international 24 (162), 192-195, 2015 | 29 | 2015 |
| Evaluating the effects of Quebec’s private–public drug insurance system SG Morgan, MA Gagnon, M Charbonneau, A Vadeboncoeur CMAJ 189 (40), E1259-E1263, 2017 | 26 | 2017 |
| A better prescription: advice for a national strategy on pharmaceutical policy in Canada SG Morgan, MA Gagnon, B Mintzes, J Lexchin Healthcare policy 12 (1), 18, 2016 | 24 | 2016 |
| Drug shortages: searching for a cure MA Gagnon Healthcare Policy 7 (4), 10, 2012 | 22 | 2012 |
| Les réseaux de l’internationalisme statistique (1885-1914) MA Gagnon L’ère du chiffre. Systèmes statistiques et traditions nationales, Québec …, 2000 | 21 | 2000 |
| Achieving greater independence from commercial influence in research J Lexchin, LA Bero, C Davis, MA Gagnon bmj 372, 2021 | 19 | 2021 |
| Recherche clinique sous influence: penser les alternatives MA Gagnon Rev Prescrire 32 (342), 311-314, 2012 | 19* | 2012 |
Dimitri DELLA FAILLEProfesseur, Département des sciences sociales, Université du Québec en OutaouaisZweryfikowany adres z uqo.ca
